These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

116 related articles for article (PubMed ID: 34169625)

  • 1. Dasiglucagon, a next-generation glucagon analogue, for treatment of severe hypoglycaemia via an autoinjector device: Results of a phase 3, randomized, double-blind trial.
    Bailey TS; Willard J; Klaff LJ; Yager Stone J; Melgaard A; Tehranchi R
    Diabetes Obes Metab; 2021 Oct; 23(10):2329-2335. PubMed ID: 34169625
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Dasiglucagon-A Next-Generation Glucagon Analog for Rapid and Effective Treatment of Severe Hypoglycemia: Results of Phase 3 Randomized Double-Blind Clinical Trial.
    Pieber TR; Aronson R; Hövelmann U; Willard J; Plum-Mörschel L; Knudsen KM; Bandak B; Tehranchi R
    Diabetes Care; 2021 Jun; 44(6):1361-1367. PubMed ID: 35239971
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Dasiglucagon, a next-generation ready-to-use glucagon analog, for treatment of severe hypoglycemia in children and adolescents with type 1 diabetes: Results of a phase 3, randomized controlled trial.
    Battelino T; Tehranchi R; Bailey T; Dovc K; Melgaard A; Yager Stone J; Woerner S; von dem Berge T; DiMeglio L; Danne T
    Pediatr Diabetes; 2021 Aug; 22(5):734-741. PubMed ID: 33934456
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Low doses of dasiglucagon consistently increase plasma glucose levels from hypoglycaemia and euglycaemia in people with type 1 diabetes mellitus.
    Hövelmann U; Olsen MB; Mouritzen U; Lamers D; Kronshage B; Heise T
    Diabetes Obes Metab; 2019 Mar; 21(3):601-610. PubMed ID: 30350477
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Integrated safety and efficacy analysis of dasiglucagon for the treatment of severe hypoglycaemia in individuals with type 1 diabetes.
    Heller S; Battelino T; Bailey TS; Pieber TR; Hövelmann U; Plum-Mörschel L; Melgaard AE; Aronson R; DiMeglio LA; Johansen T; Danne T
    Diabetes Obes Metab; 2023 May; 25(5):1351-1360. PubMed ID: 36692230
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Dasiglucagon: an effective medicine for severe hypoglycemia.
    Xu B; Tang G; Chen Z
    Eur J Clin Pharmacol; 2021 Dec; 77(12):1783-1790. PubMed ID: 34223944
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pharmacokinetic and Pharmacodynamic Characteristics of Dasiglucagon, a Novel Soluble and Stable Glucagon Analog.
    Hövelmann U; Bysted BV; Mouritzen U; Macchi F; Lamers D; Kronshage B; Møller DV; Heise T
    Diabetes Care; 2018 Mar; 41(3):531-537. PubMed ID: 29273578
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pen-administered low-dose dasiglucagon vs usual care for prevention and treatment of non-severe hypoglycaemia in people with type 1 diabetes during free-living conditions: a Phase II, randomised, open-label, two-period crossover trial.
    Laugesen C; Ranjan AG; Schmidt S; Nørgaard K
    Diabetologia; 2023 Jul; 66(7):1208-1217. PubMed ID: 37037948
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Evaluating dasiglucagon as a treatment option for hypoglycemia in diabetes.
    Li S; Hu Y; Tan X; Wang D; Hu J; Zou P; Wang L
    Expert Opin Pharmacother; 2020 Aug; 21(11):1311-1318. PubMed ID: 32267182
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Dasiglucagon: First Approval.
    Blair HA
    Drugs; 2021 Jun; 81(9):1115-1120. PubMed ID: 34047955
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Immunogenicity of the Novel Glucagon Analogue Dasiglucagon: Results of a Dedicated Immunogenicity Trial in Type 1 Diabetes.
    Pieber TR; Ajala O; Steen O; Dahl D; Hansen LE; Tehranchi R
    Diabetes Technol Ther; 2021 Nov; 23(11):773-776. PubMed ID: 34252289
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A Comparative Study of Dasiglucagon Ready-to-Use Autoinjector and Glucagon Emergency Kit During Rescue from Simulated Severe Hypoglycemia.
    Bailey NC; Dimsits J; Hammer M; Kendall DM; Bailey TS
    Diabetes Technol Ther; 2022 Apr; 24(4):231-240. PubMed ID: 34809479
    [No Abstract]   [Full Text] [Related]  

  • 13. Low-Dose Dasiglucagon Versus Oral Glucose for Prevention of Insulin-Induced Hypoglycemia in People With Type 1 Diabetes: A Phase 2, Randomized, Three-Arm Crossover Study.
    Laugesen C; Ranjan AG; Schmidt S; Nørgaard K
    Diabetes Care; 2022 Jun; 45(6):1391-1399. PubMed ID: 35475907
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Dasiglucagon Effectively Mitigates Postbariatric Postprandial Hypoglycemia: A Randomized, Double-Blind, Placebo-Controlled, Crossover Trial.
    Nielsen CK; Øhrstrøm CC; Kielgast UL; Hansen DL; Hartmann B; Holst JJ; Lund A; Vilsbøll T; Knop FK
    Diabetes Care; 2022 Jun; 45(6):1476-1481. PubMed ID: 35320361
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Dasiglucagon for treating severe hypoglycemia in patients with diabetes.
    Ju Y; Zhang D; Yang J
    Expert Rev Clin Pharmacol; 2022 Jul; 15(7):799-803. PubMed ID: 35848442
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Clinical efficacy and safety of dasiglucagon in severe hypoglycemia associated with patients of type 1 diabetes mellitus: a systematic review and meta-analysis.
    Dholariya S; Parchwani D; Dutta S; Singh R
    Expert Rev Clin Pharmacol; 2023 Jan; 16(1):61-71. PubMed ID: 36266088
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Dasiglucagon Treatment for Postprandial Hypoglycemia After Gastric Bypass: A Randomized, Double-Blind, Placebo-Controlled Trial.
    Nielsen CK; Øhrstrøm CC; Houji IJK; Helsted MM; Krogh LSL; Johansen NJ; Hartmann B; Holst JJ; Vilsbøll T; Knop FK
    Diabetes Care; 2023 Dec; 46(12):2208-2217. PubMed ID: 37819999
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Dasiglucagon for the Treatment of Insulin-induced Hypoglycemia in Patients with Type 1 Diabetes Mellitus: A Meta-analysis.
    Maji S; Mohanty RR; Maiti R
    Balkan Med J; 2023 Oct; 40(6):400-408. PubMed ID: 37735694
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Dasiglucagon demonstrates reduced costs in the treatment of severe hypoglycemia in a budget impact model.
    Hinahara J; Weinzimer SA; Bromley ER; Goss TF; Kendall DM; Hammer M
    J Manag Care Spec Pharm; 2022 Apr; 28(4):461-472. PubMed ID: 35332789
    [No Abstract]   [Full Text] [Related]  

  • 20. Dasiglucagon: A Novel Ready-to-Use Treatment for Severe Hypoglycemia.
    Goodhart AL
    Ann Pharmacother; 2023 Mar; 57(3):300-305. PubMed ID: 35861467
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.